ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

Therapy resistance is a major clinical problem in cancer medicine and crucial for disease relapse and progression. Therefore, the clinical need to overcome it, particularly for aggressive tumors such as pancreatic cancer, is very high. Aberrant activation of an epithelial–mesenchymal transition (EMT...

Full description

Saved in:
Bibliographic Details
Published in:EMBO Mol Med
Main Authors: Meidhof, Simone, Brabletz, Simone, Lehmann, Waltraut, Preca, Bogdan-Tiberius, Mock, Kerstin, Ruh, Manuel, Schüler, Julia, Berthold, Maria, Weber, Anika, Burk, Ulrike, Lübbert, Michael, Puhr, Martin, Culig, Zoran, Wellner, Ulrich, Keck, Tobias, Bronsert, Peter, Küsters, Simon, Hopt, Ulrich T, Stemmler, Marc P, Brabletz, Thomas
Format: Artigo
Language:Inglês
Published: BlackWell Publishing Ltd 2015
Subjects:
Research Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459821/
https://ncbi.nlm.nih.gov/pubmed/25872941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201404396
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items